Obstet Gynecol Sci.  2020 Apr;63(3):337-345. 10.5468/ogs.2020.63.3.337.

Medically unfit women with early-stage endometrial cancer treated with the levonorgestrel intrauterine system

• Nikolopoulos M
• Godfrey MA
• Wuntakal R

• KMID: 2500424
• DOI: http://doi.org/10.5468/ogs.2020.63.3.337

Abstract

Objective
To assess the clinical efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the treatment of early-stage endometrial cancer in elderly morbidly obese women, whose multiple co-morbidities made the standard surgical treatment too risky to undertake.
Methods
A retrospective review was conducted and case series reports were prepared of all women diagnosed with endometrial cancer, from April 2011 to December 2016 at the Queen's Hospital, London, to identify women unfit for surgery and treated with the LNG-IUS.
Results
Out of 438 women with endometrial cancer, Eight women with early-stage endometrial cancer were deemed unfit for surgery and underwent treatment with the LNG-IUS. All had grade 1 endometrioid endometrial adenocarcinoma, radiologically staged as 1a. Four women died of their co-morbidities, not related to endometrial cancer. One of them had 68 months of progression-free survival before death due to co-morbidities. One patient required a hysterectomy after 32 months of treatment with LNG-IUS and oral progestogens due to heavy vaginal bleeding. Three women have continued the LNG-IUS treatment with no evidence of progressive disease symptoms till date at a mean follow-up of 35.7 months.
Conclusion
For women with multiple co-morbidities, the LNG-IUS offers an effective and safe treatment for early-stage, lowgrade endometrial cancer, with no cases of symptomatic progression reported in our case series. In the frail and elderly, where the quality of life is of paramount importance, surgical treatment may not offer additional long-term survival benefits.

Keyword

Endometrial cancer; Quality of life; Elderly; Levonorgestrel; Mirena

Figure

• 

  Fig. 1 Study flow chart of the medically very high risk and/or unfit women treated with LNG-IUS for stage 1, grade 1 endometrial adenocarcinoma.LNG-IUS, levonorgestrel intrauterine system.

Reference

1. Sletten ET, Arnes M, Vereide AB, Ørbo A. Low-dose LNG-IUS as therapy for endometrial hyperplasia. A prospective cohort pilot study. Anticancer Res. 2018; 38:2883–2889. PMID: 29715112.

2. Cancer Research UK. Uterine cancer incidence statistics, risk, survival and mortality rates 2018 [Internet]. Oxford: Cancer Research UK;2018. cited 2018 Dec 28. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/incidence.

3. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011; 205:518–525. PMID: 21802066.

4. Baker WD, Pierce SR, Mills AM, Gehrig PA, Duska LR. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol Oncol. 2017; 146:34–38. PMID: 28427775.

5. Passarello K, Kurian S, Villanueva V. Endometrial cancer: an overview of pathophysiology, management, and care. Semin Oncol Nurs. 2019; 35:157–165. PMID: 30867105.

6. Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol. 2018; 25:308–313. PMID: 28782618.

7. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012; 125:477–482. PMID: 22245711.

8. Chiva L, Lapuente F, González-Cortijo L, Carballo N, García JF, Rojo A, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008; 111(Suppl):S101–S104. PMID: 18804267.

9. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012; 207:266.e1–266.e12. PMID: 23021687.

10. Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, et al. European Society of Gynecological Oncology task force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer. 2015; 25:1258–1265. PMID: 26186070.

11. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005; 97:924–927. PMID: 15943993.

12. Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004; 95:762–764. PMID: 15582001.

13. Bouwman F, Smits A, Lopes A, Das N, Pollard A, Massuger L, et al. The impact of BMI on surgical complications and outcomes in endometrial cancer surgery--an institutional study and systematic review of the literature. Gynecol Oncol. 2015; 139:369–376. PMID: 26407479.

14. Rolston A, Spencer RJ, Kevin Reynolds R, Rice LW, Uppal S. Factors associated with outcomes and inpatient 90-day cost of care in endometrial cancer patients undergoing hysterectomy - implications for bundled care payments. Gynecol Oncol. 2018; 150:106–111. PMID: 29778507.

15. Caldwell G, Ragupathy K. Mirenas against malignancy: an alternative to operative management. J Obstet Gynaecol. 2018; 38:731. PMID: 29944040.

16. Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis. Ann Surg Oncol. 2017; 24:1322–1329. PMID: 27896507.

17. Macchia G, Deodato F, Cilla S, Legge F, Carone V, Chiantera V, et al. Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment. Oncol Lett. 2016; 11:3446–3450. PMID: 27123133.

18. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002; 186:651–657. PMID: 11967486.

19. Morelli M, Di Cello A, Venturella R, Mocciaro R, D'Alessandro P, Zullo F. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecol Endocrinol. 2013; 29:156–159. PMID: 23134558.

20. Wildemeersch D. Safety and comfort of long-term continuous combined transdermal estrogen and intrauterine levonorgestrel administration for postmenopausal hormone substitution - a review. Gynecol Endocrinol. 2016; 32:598–601. PMID: 27117308.

21. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014; 121:477–486. PMID: 24286192.

22. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol. 2016; 55:1281–1284. PMID: 27148621.

23. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014; 124:292–299. PMID: 25004338.

24. Jareid M, Thalabard JC, Aarflot M, Bøvelstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018; 149:127–132. PMID: 29482839.

25. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017; 377:2228–2239. PMID: 29211679.

26. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017; 28:e2. PMID: 27670256.

27. Heyman J. The radiotherapeutic treatment of cancer corporis uteri. Br J Radiol. 1947; 20:85–91. PMID: 20289010.

28. van der Steen-Banasik E. Primary brachytherapy as a radical treatment for endometrial carcinoma. J Contemp Brachytherapy. 2014; 6:106–112. PMID: 24790629.

29. Dankulchai P, Petsuksiri J, Chansilpa Y, Hoskin PJ. Image-guided high-dose-rate brachytherapy in inoperable endometrial cancer. Br J Radiol. 2014; 87:20140018. PMID: 24807067.

30. Kucera H, Knocke TH, Kucera E, Pötter R. Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstet Gynecol Scand. 1998; 77:1008–1012. PMID: 9849846.

31. Nguyen TV, Petereit DG. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol. 1998; 71:196–203. PMID: 9826460.

32. Jordan SE, Micaily I, Hernandez E, Ferriss JS, Miyamoto CT, Li S, et al. Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. Brachytherapy. 2017; 16:1144–1151. PMID: 28958736.

33. Petereit DG, Sarkaria JN, Chappell RJ. Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy. Int J Radiat Oncol Biol Phys. 1998; 42:1025–1031. PMID: 9869225.